Perception and Prevalence of Fungal Infections in Berlin - Brandenburg (IFI_ICU)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Claudia Spies, Charite University, Berlin, Germany
ClinicalTrials.gov Identifier:
NCT01393002
First received: July 5, 2011
Last updated: October 17, 2013
Last verified: October 2013

July 5, 2011
October 17, 2013
July 2011
July 2012   (final data collection date for primary outcome measure)
Perception and prevalence of fungal infections [ Time Frame: 4 months ] [ Designated as safety issue: No ]
Perception and prevalence of fungal infections in ICU patients differs from real prevalence and leads to insufficient attribution of importance to this special medical condition.
Same as current
Complete list of historical versions of study NCT01393002 on ClinicalTrials.gov Archive Site
Practice - Surrogate markers for diagnosis and therapy of fungal infection and retrospective analysis of cases of invasive mycosis in a peer-review setting. [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Qualitative and quantitative estimation of surrogate markers for diagnosis and treatment of invasive mycosis

Number of bloodcultures per year Rate of bloodcultures positive for fungi ICD-10 diagnosis ICU length of stay for patients with invasive mycosis and/or fungal infection Hospital mortality for patients with invasive mycosis and/or fungal infection Number of patients treated by antimycotics per year Mean duration of antifungal treatment Defined daily doses of antimycotics given by hospital pharmacy

Same as current
Not Provided
Not Provided
 
Perception and Prevalence of Fungal Infections in Berlin - Brandenburg
Web-based Structured Survey of Retrospective Data of Invasive Mycosis in Intensive Care Patients in Berlin - Brandenburg

This is a structured web-based survey in selected hospitals with intensive care units in Berlin- Brandenburg that will focus on the analysis of current knowledge in ICUs in the field of invasive mycoses.

Intensive care patients with invasive mycosis require a special clinical expertise especially in light of a high lethality. Early identification of patients at risk to develop a fungal infection is of utmost importance to start effective antifungal therapy. The implementation of current knowledge into clinical practice to fight fungal infection is not clear.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Intensive care units of different primary and secondary care hospitals in the region of Berlin-Brandenburg.

Invasive Mycosis
Not Provided
INABBRA
Participating hospitals in the INABBRA alliance.
Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005 Sep;49(9):3640-5.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
July 2013
July 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Intensive care units of hospitals in the INABBRA alliance.
  • Patients with invasive mycosis.

Exclusion Criteria:

  • Hospitals without intensive care unit.
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT01393002
IFI_ICU
No
Claudia Spies, Charite University, Berlin, Germany
Charite University, Berlin, Germany
Not Provided
Study Director: Claudia Spies, Prof., MD Department of Anesthesiology and Intensive Care Medicine, Campus Virchow-Klinikum and Campus Charité Mitte, Charité - Universitaetsmedizin Berlin
Charite University, Berlin, Germany
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP